Fiche société
Alder Biopharmaceuticals, Inc.
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications2liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| ALD403The purpose of this study is to assess the safety, pharmacokinetics and efficacy of a single dose of ALD403 in the prevention of migraine headache in frequent episodic migraineurs for 24 weeks. | Migraine | Phase 1 | À vérifier | United States | À vérifier |
| ALD403The purpose of this study is to assess the safety, pharmacokinetics and efficacy of a single dose of ALD403 in the prevention of migraine headache in frequent episodic migraineurs for 24 weeks. | Migraine | Phase 1 | À vérifier | United States | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| ALD403 | Migraine | Phase 1 | NCT01772524 | Safety, Efficacy and Pharmacokinetics of ALD403 | COMPLETED |
Publications
2| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| ALD403 | Treatment with eptinezumab for migraine prevention in people with chronic migraine and medication-overuse headache: a plain language summary. | Pain management | ||
| ALD403 | Review: An Update on CGRP Monoclonal Antibodies for the Preventive Treatment of Episodic Migraine. | Current pain and headache reports |